NRG Therapeutics
Disease-modifying neuro therapeutics targeting mitochondrial dysfunction
NRG Therapeutics is developing first-in-class, oral, small molecule neuroprotective therapeutics targeting mitochondrial dysfunction and neuroinflammation for treatment of neurodegenerative and peripheral diseases. Its lead program reduces mitochondrial permeability transition pore (mPTP) formation to restore mitochondrial function. The program has broad potential with initial focus on ALS and PD and will enter the clinic in 2025.
NRG is headquartered in the UK and supported by experienced biotech investors, including M Ventures, SV Health Investors’ Dementia Discovery Fund, British Business Bank, Novartis Venture Fund, Criteria BioVentures, Omega Funds, Brandon Capital and Parkinson’s UK.
